Clinical trial · Observational
VALEO: A Post Authorization Study, Designed to Learn More About the Safety and Effectiveness of the Use of Bortezomib in the Netherlands
A Post Authorization Study, Designed to Learn More About the Safety and Efficacy of the Use of VELCADE (Bortezomib) in the Netherlands
NCT00440765CI-TRIAL-00013456completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The main purpose of this study is to evaluate safety and effectiveness of the treatment of multiple myeloma with bortezomib in daily practice in the Netherlands.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hematological Neoplasms | Hematopoietic and Lymphoid Cell Neoplasm | ALIAS | 0.90 |
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| bortezomib | Drug | Bortezomib | ALIAS |
Design
Arms and outcomes
Arms (1)
- label
- 001
- description
- bortezomib dose as determined (observational study) by treating physician
- interventionNames
- Drug: bortezomib
Primary outcomes (1)
- measure
- Response to treatment; determination of response, duration of response, determination of relapse/progression
- timeFrame
- no timepoints are defined, as this is an observational study; data will be collected until three years after last bortezomib administration.
Secondary outcomes (4)
- measure
- bortezomib treatment schedule used
- timeFrame
- each cycle
- measure
- combination therapies for multiple myeloma
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients have to sign a statement that they agree with collection of their clinical data for this project * the patient is eligible, in the investigator's opinion, based on the criteria in the summary of product characteristics for bortezomib Exclusion Criteria: * If patients meet the eligibility criteria, there are no exclusion criteria.
References
Publications (0)
Data not yet available
No reference posted for this study.